Medicus Pharma Ltd (NASDAQ:MDCX) Given Consensus Recommendation of “Hold” by Analysts
by Teresa Graham · The Cerbat GemShares of Medicus Pharma Ltd (NASDAQ:MDCX – Get Free Report) have been given a consensus recommendation of “Hold” by the five ratings firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $14.50.
MDCX has been the subject of several research analyst reports. Roth Mkm initiated coverage on shares of Medicus Pharma in a research report on Tuesday. They issued a “buy” rating for the company. D. Boral Capital reissued a “buy” rating and issued a $9.00 price target on shares of Medicus Pharma in a research note on Monday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Medicus Pharma in a research report on Friday, April 10th.
Get Our Latest Stock Report on MDCX
Hedge Funds Weigh In On Medicus Pharma
Several institutional investors and hedge funds have recently added to or reduced their stakes in MDCX. Private Advisor Group LLC grew its position in shares of Medicus Pharma by 3.8% in the 3rd quarter. Private Advisor Group LLC now owns 151,500 shares of the company’s stock worth $351,000 after buying an additional 5,500 shares during the period. Osaic Holdings Inc. boosted its stake in Medicus Pharma by 180.0% during the second quarter. Osaic Holdings Inc. now owns 14,000 shares of the company’s stock worth $42,000 after acquiring an additional 9,000 shares in the last quarter. Jane Street Group LLC purchased a new stake in Medicus Pharma in the second quarter worth about $41,000. Commonwealth Equity Services LLC increased its stake in shares of Medicus Pharma by 161.8% during the fourth quarter. Commonwealth Equity Services LLC now owns 28,493 shares of the company’s stock valued at $44,000 after purchasing an additional 17,611 shares in the last quarter. Finally, May Hill Capital LLC lifted its holdings in shares of Medicus Pharma by 100.0% during the fourth quarter. May Hill Capital LLC now owns 35,622 shares of the company’s stock valued at $55,000 after purchasing an additional 17,811 shares during the last quarter.
Medicus Pharma Price Performance
Shares of NASDAQ:MDCX opened at $0.35 on Tuesday. The stock’s 50-day moving average is $0.71 and its 200 day moving average is $1.47. The company has a market cap of $13.74 million, a PE ratio of -0.12 and a beta of 1.16. Medicus Pharma has a 1 year low of $0.29 and a 1 year high of $8.94.
Medicus Pharma (NASDAQ:MDCX – Get Free Report) last issued its quarterly earnings data on Thursday, March 26th. The company reported ($0.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.50). Analysts expect that Medicus Pharma will post -0.54 EPS for the current fiscal year.
Medicus Pharma Company Profile
Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.
Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.